Siriwardana, R.C.Liyanage, C.A.H.L.Jayatunge, D.S.P.Dassanayake, A.Gunetileke, M.G.Niriella, M.A.Sirigampola, C.Upasena, A.de Silva, H.J.2016-02-102016-02-102013Sri Lanka Medical Association, 126th Anniversary Scientific Medical Congress. 2013; 58 Supplement 1: 290009-0895http://repository.kln.ac.lk/handle/123456789/11620Oral Presentation Abstract (OP 45), 126th Anniversary Scientific Medical Congress, Sri Lanka Medical Association, 10th-13th July 2013 Colombo, Sri LankaINTRODUCTION AND OBJECTIVES:Hepato-cellular carcinoma (HCC) is the sixth commonest cancer worldwide. We studied 105 consecutive patients with HCC in a single tertiary care centre. METHODS: North Colombo Liver Unit maintains a prospective database of HCC since September 2011. There were 105 entries by February 2013. Decision on the best form of treatment was taken at a multidisciplinary meeting. RESULTS: The median age at presentation was 63 years (range 12-79). Patients were predominantly male 93 (87%). Alcohol consumption above the safe limit was reported in 47 (45%). Hepatitis B surface antigen or C antibody was not detected in any of the patients. Background liver cirrhosis was evident in 59 (79%). Forty two (46%) patients had single nodular tumours while in 20 (21%) it was diffusely infiltrating. Portal vein invasion was seen in 22 (20 %). Median alpha-feto protein (AFP) level was 57.25 mg/ml (1.16- 94120 ng/ml; n=72). Twenty four (33%) patients had AFP level > 400u/l. Surgery was performed in 20 (19%), liver transplant in 2 (1.9%), radiofrequency ablation or alcohol ablation in 8 (7.6%), trans arterial chemo embolization (TACE) in 44 (41.9%) and sorafinib was prescribed .in four patients. Overall mean survival was 15 months. In the 'no treatment' group, mean survival was 4 months. Surgery group had a mean survival of 20 months. CONCLUSION: Hepatitis B is not a risk factor for HCC in Sri Lankans. Median survival without treatment is 4 months.en-USCarcinoma, HepatocellularConference Abstract